K. Jung

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

M. Piccart, S. Lakhani, K. Gelmon, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

J. Jassem, P. Wysocki, P. Schmid, 2022, Annals of Oncology.

Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis.

J. Lee, H. Lee, K. Jung, 2004, Journal of Clinical Oncology.

LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

H. Iwata, L. Molinero, N. Harbeck, 2020 .

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Tong Xu, L. Molinero, K. Punie, 2023, ESMO Open.